Description: The presenters describe the process payers and employers can use to evaluate emerging medical device technologies, recent or pending FDA submissions for prescription drugs and experimental treatments that impact patient care, resource utilization and health care expenditures. Learn the process of identifying and selecting impactful treatments (Horizon Scanning) and quantifying the financial cost of new technologies before they arrive in the market. These workflows can be leveraged by actuaries, healthcare economists, clinicians and pharmacists from a payer (Commercial and Medicare) and employer perspective for self-funded plans. Walk through sample models that illustrate how costs for emerging technologies and treatments can be modeled.

Description: This presentation, session number 102PD, took place at the 1999 Spring Meeting of the Society of Actuaries, held June 16-18 in Seattle. The panelists discuss the popularity of such voluntary products as critical illness, group AD&D, and group long-term disability, and their implications for reinsurers. Discussion from participants is included. From the Record of the Society of Actuaries, Vol. 25, No. 2.

Description: This presentation is a panel discussion, session 66PD, from the 2004 Spring Meeting of the Society of Actuaries, held June 14-15 in San Antonio, TX. Noting that life insurance and annuity products in general have grown much more complex [e.g. universal life with secondary guarantees], the panelists discuss the product development process and the resources you can use to get the product to market quickly. They discuss topics including the product development cycle, reinsurance assistance, and filing with state insurance departments and the Securities and Exchange Commission [SEC]. Discussion from participants is included. From the Record of Society of Actuaries, Volume 30, No. 2.